IHT Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

IHT Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-66	Closed	-$5K	–	531
2018 Q1	$5K	Sell	66 -74	-53%	-$6.35K	﹤0.01%	1331
2017 Q4	$12K	Hold	140	–	–	﹤0.01%	1127
2017 Q3	$13K	Buy	140 +28	+25%	+$2.47K	0.01%	881
2017 Q2	$15K	Hold	112	–	–	0.01%	848
2017 Q1	$10K	Buy	112 +55	+96%	+$4.89K	0.01%	832
2016 Q4	$5K	Buy	+57	New	+$4.9K	﹤0.01%	905

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

IHT Wealth Management's BMRN Position: Q2 2018 in Review

IHT Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 66 shares — an estimated $5K sold.

IHT Wealth Management first reported a position in BMRN in Q4 2016 and held it in 6 quarters. The position peaked at $15K in Q2 2017. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

IHT Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
IHT Wealth Management sold 66 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $5K.
IHT Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 6 quarters.
IHT Wealth Management's BioMarin Pharmaceuticals position peaked at $15K in Q2 2017.
449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.